Because they target completely different regions of the HER2 receptor, we addressed a potential benefit of the association between ebselen oxide and standard anti‐HER2 therapeutic agents in HER2‐positive cancer cells, from breast (SKBR3 and BT474) or gastric (NCI‐N87) origin. This evidence concerns the gene ERBB2 and cancer.